Rybski J A, Spier C M, Miller T P, Lippman S M, McGee D L, Grogan T M
a Departments of Pathology and Internal Medicine and the Arizona Cancer Center, University of Arizona, Tucson, Arizona, USA.
Leuk Lymphoma. 1991;6(1):31-8. doi: 10.3109/10428199109064876.
Ninety-nine consecutive diffuse large cell lymphoma (DLCL) patients were studied by immunohistochemistry to determine whether clinical outcome was predicted by major histocompatibility complex (MHC) antigen phenotypic expression. Statistically significantly shorter disease free survival (p = 0.005), but not overall survival (p = 0.47), was observed when patient lymphomas failed to express class I MHC antigens. We also observed significantly reduced survival of class II MHC HLA-DP negative patients (p = 0.038). This extends our previous finding of poor outcome with absent class II MHC HLA-DR in DLCL(1) to other MHC antigens and demonstrates that the phenomenon of defective class II antigen expression comprises 16% of these DLCL patients. Known clinical parameters predictive of prognosis were equally distributed between phenotypic groups. These findings indicate that aberrancy of immune phenotype in DLCL is critical to patient outcome and we speculate that loss of MHC expression may confound host immunosurveillance and tumor containment.
对99例连续性弥漫性大细胞淋巴瘤（DLCL）患者进行免疫组化研究，以确定主要组织相容性复合体（MHC）抗原表型表达是否可预测临床结局。当患者淋巴瘤不表达I类MHC抗原时，观察到无病生存期显著缩短（p = 0.005），但总生存期无显著差异（p = 0.47）。我们还观察到II类MHC HLA-DP阴性患者的生存期显著缩短（p = 0.038）。这将我们之前在DLCL中发现的II类MHC HLA-DR缺失导致预后不良的结果（1）扩展到了其他MHC抗原，并表明II类抗原表达缺陷现象在这些DLCL患者中占16%。已知的预测预后的临床参数在表型组之间分布均匀。这些发现表明，DLCL中免疫表型异常对患者结局至关重要，我们推测MHC表达缺失可能会混淆宿主免疫监视和肿瘤控制。
